【北京，中国 – BusinessWire】全球领先的人工智能个性化手术医疗科技公司Carlsmed近日宣布，成功完成了一轮5250万美元的C轮融资，本轮融资由知名投资机构B Capital和US Venture Partners共同领投。这笔资金的注入将显著推动Carlsmed在医疗科技领域的创新步伐，尤其是对其aprevo ®个性化脊柱手术平台的商业化进程产生重要影响。
Carlsmed的aprevo ®平台在腰椎融合手术中已展现出显著的技术优势，为医生提供了高度精确的手术规划和执行工具。随着新资金的到位，公司将加快这一平台的市场推广，让更多患者受益于这一革命性的医疗技术。同时，Carlsmed还计划将aprevo ®的技术拓展至颈椎融合手术领域，预计全新的颈椎手术平台将于2025年正式推出。
此次融资的成功，不仅彰显了投资者对Carlsmed技术潜力和市场前景的坚定信心，也标志着人工智能在医疗手术个性化领域的应用进入了新的发展阶段。Carlsmed将继续致力于利用人工智能技术优化手术流程，提高手术安全性和疗效，以满足全球不断增长的精准医疗需求。
Carlsmed的首席执行官在声明中表示：“我们非常感谢B Capital和US Venture Partners的支持，他们的投资将帮助我们加速aprevo ®平台的商业化，以及推进颈椎手术平台的研发。我们期待通过创新的力量，改变脊柱手术的未来，为全球患者提供更优质、更个性化的医疗服务。”
关于Carlsmed
Carlsmed是一家专注于人工智能驱动的个性化手术解决方案的医疗科技公司，其aprevo ®平台已经在腰椎手术中取得了显著成果，未来将进一步扩展到颈椎手术领域，致力于通过精准医疗技术改善患者的生活质量。
英语如下：
**News Title:** “Carlsmed Raises $52.5 Million in Series C Financing to Accelerate Growth of its Personalized Spine Surgery Platform, aprevo ®”
**Keywords:** Carlsmed, Artificial Intelligence, Surgical Platform
**News Content:**
**BEIJING, China – BusinessWire** – Carlsmed, a global leader in artificial intelligence (AI)-powered personalized surgery, recently announced the successful completion of a $52.5 million Series C funding round, co-led by prominent investors B Capital and US Venture Partners. This injection of capital will significantly boost Carlsmed’s innovation in the medical technology sector, particularly in the commercialization of its aprevo ® personalized spine surgery platform.
Carlsmed’s aprevo ® platform has demonstrated substantial technological advantages in lumbar fusion surgeries, providing surgeons with highly precise planning and execution tools. With the new funding, the company will accelerate the platform’s market expansion, enabling more patients to benefit from this groundbreaking medical technology. Additionally, Carlsmed plans to extend the aprevo ® technology to cervical fusion surgeries, with an anticipated launch of a new cervical surgery platform in 2025.
The successful financing round underscores investors’ confidence in Carlsmed’s technological potential and market prospects, signifying a new chapter in the application of AI in personalized surgical care. Carlsmed remains dedicated to leveraging AI to optimize surgical workflows, enhance surgical safety and efficacy, addressing the global demand for precision medicine.
The CEO of Carlsmed stated, “We are grateful for the support from B Capital and US Venture Partners. Their investment will propel the commercialization of the aprevo ® platform and the development of our cervical surgery offering. We look forward to transforming the future of spinal surgery and delivering higher quality, personalized care to patients worldwide through innovation.”
**About Carlsmed**
Carlsmed is a medical technology company specializing in AI-driven personalized surgical solutions. Its aprevo ® platform has made significant strides in lumbar surgeries and is poised to expand into cervical surgeries, striving to improve patients’ quality of life through precision medical technologies.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1